Public Drug Program Formulary Tables – Psoriasis and Psoriatic Arthritis

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsAbataceptOrencia®N/ANohttps://pdf.hres.ca/dpd_pm/00045017.PDFhttps://pdf.hres.ca/dpd_pm/00066773.PDFJuly 21, 2022
AlbertaBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDFNov 14, 2022
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®NoNoNAhttps://pdf.hres.ca/dpd_pm/00067468.PDF9 September, 2022
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068763.PDFDec 14, 2022
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068848.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabHumira®No No https://pdf.hres.ca/dpd_pm/00052133.PDFhttps://pdf.hres.ca/dpd_pm/00068848.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00067757.PDFOctober 11, 2022
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00058541.PDFOctober 30, 2020
AlbertaBiologics and BiosimilarsAdalimumabSIMLANDI™Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068814.PDFDec 9, 2022
AlbertaBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00069429.PDFFebruary 3, 2023
AlbertaBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/Ahttps://pdf.hres.ca/dpd_pm/00064702.PDFhttps://pdf.hres.ca/dpd_pm/00064702.PDFFebruary 14, 2022
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/Ahttps://pdf.hres.ca/dpd_pm/00044076.PDFhttps://pdf.hres.ca/dpd_pm/00051682.PDFJune 7, 2019
AlbertaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00049574.PDFhttps://pdf.hres.ca/dpd_pm/00053920.PDFNovember 13, 2019
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/ANAhttps://pdf.hres.ca/dpd_pm/00065129.PDFMarch 17, 2022
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes - pediatric patients weighing less than 63 kgNohttps://pdf.hres.ca/dpd_pm/00048003.PDFhttps://pdf.hres.ca/dpd_pm/00060454.PDFMarch 19, 2021
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00049267.PDFhttps://pdf.hres.ca/dpd_pm/00069556.PDFJan 18, 2023
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00051840.PDFhttps://pdf.hres.ca/dpd_pm/00067454.PDFSeptember 9, 2022
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNohttps://pdf.hres.ca/dpd_pm/00057930.PDFhttps://pdf.hres.ca/dpd_pm/00068091.PDFNovember 8, 2022
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/ANAhttps://pdf.hres.ca/dpd_pm/00065940.PDFMay 17, 2022
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00059824.PDF
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo https://pdf.hres.ca/dpd_pm/00047753.PDFhttps://pdf.hres.ca/dpd_pm/00067676.PDFOct 07, 2022
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00050544.PDFhttps://pdf.hres.ca/dpd_pm/00069528.PDFFeb 09, 2023
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00047053.PDFhttps://pdf.hres.ca/dpd_pm/00057004.PDF
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi®Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00069300.PDF
AlbertaBiologics and BiosimilarsSécukinumabCosentyxᴹᴰYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067634.PDF
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/Ahttps://pdf.hres.ca/dpd_pm/00060995.PDFhttps://pdf.hres.ca/dpd_pm/00064464.PDFJanuary 24, 2022
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00048246.PDFhttps://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/stelara_cpm.pdfJanuary 5, 2023
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/Ahttps://pdf.hres.ca/dpd_pm/00034146.PDFhttps://pdf.hres.ca/dpd_pm/00055197.PDFFebruary 25, 2020
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/Ahttps://pdf.hres.ca/dpd_pm/00034364.PDFhttps://pdf.hres.ca/dpd_pm/00034364.PDFApril 4, 2016
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/Ahttps://pdf.hres.ca/dpd_pm/00036393.PDFhttps://pdf.hres.ca/dpd_pm/00065877.PDFMay 12, 2022
AlbertaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®Yes - SAN/Ahttps://pdf.hres.ca/dpd_pm/00056991.PDFhttps://pdf.hres.ca/dpd_pm/00066402.PDFJune 17, 2022
AlbertaPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/ANAhttps://pdf.hres.ca/dpd_pm/00060714.PDFApril 13, 2021
AlbertaPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYesN/Ahttps://pdf.hres.ca/dpd_pm/00031077.PDFhttps://pdf.hres.ca/dpd_pm/00031077.PDFJune 29, 2015
AlbertaPrescription Topical Treatments Vitamin_D3_Analogues (Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/ANAhttps://pdf.hres.ca/dpd_pm/00064010.PDFDecember 13, 2021
AlbertaPrescription Topical Treatments Vitamin_D3_Analogues (Dovonex® Silkis®)Silkis (calcitriol )NoN/Ahttps://pdf.hres.ca/dpd_pm/00041695.PDFhttps://pdf.hres.ca/dpd_pm/00041695.PDFOctober 17, 2017
AlbertaSystemic Drugs AcitretinSoriatane®YesN/Ahttps://pdf.hres.ca/dpd_pm/00046848.PDFhttps://pdf.hres.ca/dpd_pm/00046848.PDFAugust 10, 2018
AlbertaSystemic Drugs ApremilastOtezla®NoNohttps://pdf.hres.ca/dpd_pm/00041998.PDFhttps://pdf.hres.ca/dpd_pm/00057499.PDFAugust 5, 2020
AlbertaSystemic Drugs CelecoxibNoNohttps://pdf.hres.ca/dpd_pm/00065005.PDFMarch 10, 2022
AlbertaSystemic Drugs CyclosporineYes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00029804.PDFMarch 13, 2015
AlbertaSystemic Drugs LeflunomideArava®N/ANo
AlbertaSystemic Drugs MethotrexateMethotrexateYesYes
AlbertaSystemic Drugs SulfasalazineN/AYes
AlbertaSystemic Drugs TofacitinibXeljanz®N/AUnder review https://pdf.hres.ca/dpd_pm/00051987.PDFhttps://pdf.hres.ca/dpd_pm/00065725.PDFMay 09, 2022
AlbertaSystemic Drugs UpadacitinibRinvoqN/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068075.PDFAug 02, 2022
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®N/ANo
British ColumbiaBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSIMLANDIYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsBimekizumabBimzelxYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00064702.PDF
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
British ColumbiaBiologics and BiosimilarsCertolizumab pegol Cimzia®N/AYes - S/A
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes – S/A
British ColumbiaBiologics and BiosimilarsEtanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/A Yes – S/A
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabRemsima®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/A
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamNoN/A
British ColumbiaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
British ColumbiaPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪NoN/A
British ColumbiaPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYesN/ATazorac Cream (tazarotene): https://pdf.hres.ca/dpd_pm/00033182.PDFhttps://pdf.hres.ca/dpd_pm/00033182.PDFDecember 8, 2015
British ColumbiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
British ColumbiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
British ColumbiaSystemic Drugs AcitretinSoriatane®YesN/A
British ColumbiaSystemic Drugs ApremilastOtezla®NoNo
British ColumbiaSystemic Drugs CelecoxibNoYes – S/A
British ColumbiaSystemic Drugs CyclosporineYes – S/AN/A
British ColumbiaSystemic Drugs LeflunomideArava®NoYes - S/A
British ColumbiaSystemic Drugs MethotrexateMethotrexateYesYes
British ColumbiaSystemic Drugs SulfasalazineN/AYes
British ColumbiaSystemic Drugs TofacitinibXeljanz®N/ANo
British ColumbiaSystemic Drugs UpadacitinibRinvoqN/ANo
ManitobaBiologics and BiosimilarsAbataceptOrencia®N/ANo
ManitobaBiologics and BiosimilarsAdalimumabAbrilada®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHumira®NoNo
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsBimekizumabBimzelxYes - EDSN/A
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
ManitobaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemsima®NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDS N/A
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDS No
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
ManitobaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
ManitobaPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYesN/A
ManitobaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
ManitobaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
ManitobaSystemic Drugs AcitretinSoriataneYesN/A
ManitobaSystemic Drugs ApremilastOtezla®NoNo
ManitobaSystemic Drugs CelecoxibN/AYeshttps://pdf.hres.ca/dpd_pm/00044180.PDFhttps://pdf.hres.ca/dpd_pm/00067016.PDFAugust 4, 2022
ManitobaSystemic Drugs CyclosporineN/AYes - EDS
ManitobaSystemic Drugs LeflunomideArava®NoYes – EDS
ManitobaSystemic Drugs MethotrexateYesYeshttps://pdf.hres.ca/dpd_pm/00042486.PDFhttps://pdf.hres.ca/dpd_pm/00053187.PDFSeptember 12, 2019
ManitobaSystemic Drugs SulfasalazineN/AYes
ManitobaSystemic Drugs TofacitinibXeljanz®N/ANo
ManitobaSystemic Drugs UpadacitinibRinvoqN/ANo
ManitobaHalobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabAbrilada®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHumira®No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabSIMLANDINoNo
New BrunswickBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsBimekizumabBimzelxYes - S/ANo
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/A
New BrunswickBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes - S/A
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRemicade®No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRemsima®NonNon
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - S/AN/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes N/A
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
New BrunswickPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
New BrunswickPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYes – S/AN/A
New BrunswickPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
New BrunswickPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )YesN/A
New BrunswickSystemic Drugs AcitretinSoriatane®YesN/A
New BrunswickSystemic Drugs ApremilastOtezla®NoNo
New BrunswickSystemic Drugs CelecoxibN/AYes
New BrunswickSystemic Drugs CyclosporineYesYes
New BrunswickSystemic Drugs LeflunomideArava®N/AYes
New BrunswickSystemic Drugs MethotrexateYesYes
New BrunswickSystemic Drugs SulfasalazineN/AYes
New BrunswickSystemic Drugs TofacitinibXeljanz®N/AYes - S/A
New BrunswickSystemic Drugs UpadacitinibRinvoqN/AYes - S/A
New BrunswickHalobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®N/ANo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSIMLANDIYes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsBimekizumabBimzelxNoN/A
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only.Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only.
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; : Inflectra, Renflexis or Avsola are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Newfoundland and LabradorPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®Yes - S/AN/A
Newfoundland and LabradorPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYes – S/AN/A
Newfoundland and LabradorPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
Newfoundland and LabradorPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
Newfoundland and LabradorSystemic Drugs AcitretinSoriatane®YesN/A
Newfoundland and LabradorSystemic Drugs ApremilastOtezla®Nos.o.
Newfoundland and LabradorSystemic Drugs CelecoxibN/AYes
Newfoundland and LabradorSystemic Drugs CyclosporineYesN/A
Newfoundland and LabradorSystemic Drugs LeflunomideArava®N/AYes
Newfoundland and LabradorSystemic Drugs MethotrexateYesYes
Newfoundland and LabradorSystemic Drugs SulfasalazineN/AYes
Newfoundland and LabradorSystemic Drugs TofacitinibXeljanz®N/ANo
Newfoundland and LabradorSystemic Drugs UpadacitinibRinvoqYes- S/AN/A
Newfoundland and LabradorHalobetasol Propionate Lotion 0.01%BRYHALI🅪NoN/A
NIHBBiologics and BiosimilarsAbataceptOrencia®N/ANo
NIHBBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
NIHBBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
NIHBBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
NIHBBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
NIHBBiologics and BiosimilarsGuselkumabTremfya®NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
NIHBPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
NIHBPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
NIHBPrescription Topical Treatments Tazarotene(topical retinoids)TazoracYesN/A
NIHBPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
NIHBPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
NIHBSystemic Drugs AcitretinSoriatane®YesN/A
NIHBSystemic Drugs ApremilastOtezla®NoN/A
NIHBSystemic Drugs CelecoxibN/AYes
NIHBSystemic Drugs CyclosporineCyclosporineYesN/Ahttps://pdf.hres.ca/dpd_pm/00029804.PDFNAMarch 13, 2015
NIHBSystemic Drugs LeflunomideArava®YesYes
NIHBSystemic Drugs MethotrexateYesYes
NIHBSystemic Drugs SulfasalazineN/AYes
NIHBSystemic Drugs TofacitinibXeljanz®N/ANo
NIHBSystemic Drugs UpadacitinibRinvoqN/AYes - SA
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®N/ANo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
Northwest TerritoriesPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
Northwest TerritoriesPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
Northwest TerritoriesPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYesN/A
Northwest TerritoriesPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
Northwest TerritoriesPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
Northwest TerritoriesSystemic Drugs AcitretinSoriatane®YesN/A
Northwest TerritoriesSystemic Drugs ApremilastOtezla®NoN/A
Northwest TerritoriesSystemic Drugs CelecoxibN/AYes
Northwest TerritoriesSystemic Drugs CyclosporineYesN/A
Northwest TerritoriesSystemic Drugs LeflunomideArava®YesYes
Northwest TerritoriesSystemic Drugs MethotrexateYesYes
Northwest TerritoriesSystemic Drugs SulfasalazineN/AYes
Northwest TerritoriesSystemic Drugs TofacitinibXeljanz®N/ANo
Northwest TerritoriesSystemic Drugs UpadacitinibRinvoqN/AYes - SA
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®N/ANo
Nova ScotiaBiologics and BiosimilarsAdalimumabAbrilada®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsBimekizumabBimzelxNos.o.
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
Nova ScotiaBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes - EDS Yes - EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™Yes - EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes - EDS Yes - EDS
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDS N/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDS Yes - EDS
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDS No
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDS N/A
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – EDS N/A
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – EDS N/A
Nova ScotiaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
Nova ScotiaPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
Nova ScotiaPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYes – EDSN/A
Nova ScotiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)Yes - EDSN/A
Nova ScotiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )YesN/A
Nova ScotiaSystemic Drugs AcitretinSoriatane®YesN/A
Nova ScotiaSystemic Drugs ApremilastOtezla®NoNo
Nova ScotiaSystemic Drugs CelecoxibN/AYes
Nova ScotiaSystemic Drugs CyclosporineYesN/A
Nova ScotiaSystemic Drugs LeflunomideArava®N/AYes
Nova ScotiaSystemic Drugs MethotrexateYesYes
Nova ScotiaSystemic Drugs SulfasalazineN/AYes
Nova ScotiaSystemic Drugs TofacitinibXeljanz®N/ANo
Nova ScotiaSystemic Drugs UpadacitinibRinvoqN/AYes - EDS
NunavutBiologics and BiosimilarsAbataceptOrencia®N/ANo
NunavutBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
NunavutBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
NunavutBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
NunavutPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
NunavutPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
NunavutPrescription Topical Treatments Tazarotene(topical retinoids)TazoracYesN/A
NunavutPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
NunavutPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
NunavutSystemic Drugs AcitretinSoriatane®YesN/A
NunavutSystemic Drugs ApremilastOtezla®NoN/A
NunavutSystemic Drugs CelecoxibN/AYes
NunavutSystemic Drugs CyclosporineCyclosporineYesN/A
NunavutSystemic Drugs LeflunomideArava®YesYes
NunavutSystemic Drugs MethotrexateYesYes
NunavutSystemic Drugs SulfasalazineN/AYes
NunavutSystemic Drugs TofacitinibXeljanz®N/ANo
NunavutSystemic Drugs UpadacitinibRinvoqN/AYes - SA
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo
OntarioBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/UNAhttps://pdf.hres.ca/dpd_pm/00068228.PDFNov 14, 2022
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsBimekizumabBimzelx®Yes- L/UN/A
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
OntarioBiologics and BiosimilarsCertolizumab pegol Cimzia®NoNo
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/U No 
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsGolimumabSimponi®N/ANo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabRemicade®NoNo
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes – L/UN/A
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes N/A
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
OntarioPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
OntarioPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
OntarioPrescription Topical Treatments Tazarotene (topical retinoids)TazoracNoN/A
OntarioPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
OntarioPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )Yes – L/UN/A
OntarioSystemic Drugs AcitretinSoriatane®YesN/A
OntarioSystemic Drugs ApremilastOtezla®Yes - L/UYes - L/U
OntarioSystemic Drugs CelecoxibN/ANo
OntarioSystemic Drugs CyclosporineYesN/A
OntarioSystemic Drugs LeflunomideArava®N/AYes
OntarioSystemic Drugs MethotrexateYesYes
OntarioSystemic Drugs SulfasalazineN/AYes
OntarioSystemic Drugs TofacitinibXeljanz®N/ANo
OntarioSystemic Drugs UpadacitinibRinvoqN/ANo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®N/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbrilada®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSIMLANDIYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflyma®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/A
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes - S/AN/A
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™Yes-S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes - S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/A Yes – S/A
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™Yes-S/AN/A
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes-S/ANo
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes N/A
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Prince Edward IslandPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®Yes – S/AN/A
Prince Edward IslandPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪Yes - S/AN/A
Prince Edward IslandPrescription Topical Treatments Tazarotene (topical retinoids)NoN/A
Prince Edward IslandPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)Yes – S/AN/A
Prince Edward IslandPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )YesN/A
Prince Edward IslandSystemic Drugs AcitretinSoriatane®YesN/A
Prince Edward IslandSystemic Drugs ApremilastOtezla®NoNo
Prince Edward IslandSystemic Drugs CelecoxibN/ANo
Prince Edward IslandSystemic Drugs CyclosporineYes N/A
Prince Edward IslandSystemic Drugs LeflunomideArava®N/AYes – S/A
Prince Edward IslandSystemic Drugs MethotrexateYesYes
Prince Edward IslandSystemic Drugs SulfasalazineN/AYes – S/A
Prince Edward IslandSystemic Drugs TofacitinibXeljanz®N/ANo
Prince Edward IslandSystemic Drugs UpadacitinibRinvoqN/AYes - S/A
QuebecBiologics and BiosimilarsAbataceptOrencia®N/AYes - S/A
QuebecBiologics and BiosimilarsAdalimumabAbrilada®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/A Yes - S/A
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/A Yes – S/A
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment and reimbursement began before March 3 2021.Yes - S/A. If treatment and reimbursement began before March 3 2021.
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabSIMLANDIYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabYuflyma®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/A
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
QuebecBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment and reimbursement began before August 19 2020.Yes – S/A. If treatment and reimbursement began before August 19 2020.
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/A Yes - S/A
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment and reimburesement began before August 19, 2020 Yes – S/A. If treatment and reimburesment began before August 19, 2020 
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
QuebecPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
QuebecPrescription Topical Treatments Tazarotene (topical retinoids)TazoracOuiN/A
QuebecPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
QuebecPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )YesN/A
QuebecSystemic Drugs AcitretinSoriatane®YesN/A
QuebecSystemic Drugs ApremilastOtezla®Yes – S/AYes – S/A
QuebecSystemic Drugs CelecoxibN/AYes
QuebecSystemic Drugs CyclosporineYes
QuebecSystemic Drugs LeflunomideArava®N/AYes
QuebecSystemic Drugs MethotrexateYesYes
QuebecSystemic Drugs SulfasalazineN/AYes
QuebecSystemic Drugs TofacitinibXeljanz®N/AYes - S/A
QuebecSystemic Drugs UpadacitinibRinvoqN/AYes - S/A
QuebecHalobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®N/ANo
SaskatchewanBiologics and BiosimilarsAdalimumabAbrilada®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
SaskatchewanBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
SaskatchewanBiologics and BiosimilarsBimekizumabBimzelx®Yes – EDS N/A
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDS N/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
SaskatchewanPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
SaskatchewanPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
SaskatchewanPrescription Topical Treatments Tazarotene (topical retinoids)TazoracYesN/A
SaskatchewanPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
SaskatchewanPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
SaskatchewanSystemic Drugs AcitretinSoriatane®Yes – EDS N/A
SaskatchewanSystemic Drugs ApremilastOtezla®NoNo
SaskatchewanSystemic Drugs CelecoxibN/AYes
SaskatchewanSystemic Drugs CyclosporineYes – EDSN/A
SaskatchewanSystemic Drugs LeflunomideArava®N/AYes – EDS
SaskatchewanSystemic Drugs MethotrexateYesYes
SaskatchewanSystemic Drugs SulfasalazineN/AYes
SaskatchewanSystemic Drugs TofacitinibXeljanz®N/AYes - EDS
SaskatchewanSystemic Drugs UpadacitinibRinvoqN/AYes - EDS
YukonBiologics and BiosimilarsAbataceptOrencia®N/ANo
YukonBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
YukonBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
YukonBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
YukonBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
YukonBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
YukonBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
YukonPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
YukonPrescription Topical Treatments Halobetasol Propionate Lotion 0.01%BRYHALI🅪YesN/A
YukonPrescription Topical Treatments Tazarotene(topical retinoids)TazoracYesN/A
YukonPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Dovonex® (calcipotriol)YesN/A
YukonPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Silkis (calcitriol )NoN/A
YukonSystemic Drugs AcitretinSoriatane®YesN/A
YukonSystemic Drugs ApremilastOtezla®NoN/A
YukonSystemic Drugs CelecoxibN/AYes
YukonSystemic Drugs CyclosporineCyclosporineYesN/A
YukonSystemic Drugs LeflunomideArava®YesYes
YukonSystemic Drugs MethotrexateYesYes
YukonSystemic Drugs SulfasalazineN/AYes
YukonSystemic Drugs TofacitinibXeljanz®N/ANo
YukonSystemic Drugs UpadacitinibRinvoqN/AYes - SA

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.